| Value | ₹434.0 Cr |
|---|
BSE filing, NSE: HIKAL. Summary written from the filing by ALFA Finder's alert engine.
Hikal Ltd: key numbers
- Share price
- ₹222.61
- Market cap
- ₹2,745 Cr
- Revenue (annual)
- ₹1,713 Cr
- Net profit (annual)
- ₹-48.80 Cr
- P/E (TTM)
- -81.2×Sector 47.2×
- Promoter holding
- 68.85%+0.00% QoQ
- FII holding
- 1.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Hikal Ltd
All →Hikal Investor Presentation: Key Takeaways
Q2FY27 consolidated revenue ₹434 Cr (+36% YoY), EBITDA ₹45 Cr at 10.3% margin, PAT loss narrowed to ₹(6) Cr. Pharma led recovery; Crop Protection margins pressured.
Hikal Q2 FY27 Results: Net Loss of ₹6.1 Cr, Loss Narrows
Hikal Ltd reported revenue from operations of ₹434.2 Cr (+36.3% YoY) and a net loss of ₹6.1 Cr for Q2 FY27.
- Key figure
- Net loss ₹6.1 Cr
Hikal Bags New Order from Europe-based global agrochemical company
Hikal signed a multi-year CDMO contract with a Europe-based global agrochemical company for a specialised product. Commercial launch is expected towards the end of FY 2026-27.
- From
- Europe-based global agrochemical company (unnamed)
- Execution
- Multi-year
Hikal Regulatory Approval
Hikal's Bengaluru API facility received a Swissmedic GMP Certificate of Compliance. The certification supports wider access to European and other regulated markets.
Hikal Other Announcement
Hikal Ltd filed its quarterly shareholding pattern for the period ended 30 September 2026. The filing reports routine ownership data with no new transaction.
Hikal Board Meeting Date
Hikal's board meets November 3, 2026 to consider September quarter and half-year results. The results are yet to be approved.
Other results update announcements
All →BLS International Services Results Update
BLS International reported record Q2 FY27 revenue of Rs 973 Crore, up 32% year-on-year. H1 FY27 revenue rose 28.7% to Rs 1,863 Crore.
Cosmo First Results Update
Cosmo First released Q2 FY27 consolidated results via press release, showing EBITDA and PAT growth. Net debt was reduced while B2B and consumer businesses scaled up.
Remus Pharmaceuticals Results Update
Remus Pharmaceuticals reported H1 FY27 results with standalone revenue of ₹62.08 Cr (up 32.51%) and consolidated revenue of ₹614.12 Cr (up 53.45%). The media release also highlights new tenders, approvals and portfolio expansion across international markets.
Neuland Laboratories Results Update
Neuland Laboratories' Q2 FY27 standalone revenue fell 11.4% YoY to Rs. 457.2 Crore, with PAT at Rs. 51.1 Crore. The release lacks a full results statement.
B-Right Realestate Results Update
B-Right Realestate reported H1 FY27 consolidated revenue of Rs. 143.89 crore, up about 156%. Profit after tax rose about 160% to Rs. 9.25 crore.
ASK Automotive Results Update
ASK Automotive reported record Q2 FY27 revenue, EBITDA and PAT, with revenue up 47.5%. Results cover the quarter and half year ended September 30, 2026.
- captive solar capacity
- 11.55 MW